Drug intelligence / Profile preview

seviteronel + docetaxel

Development stage: Unknown
Lead developer: Innocrin
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Seviteronel + docetaxel is an investigational combination therapy being studied primarily for metastatic triple-negative breast cancer (TNBC). Seviteronel (INO-464) is a selective CYP17 lyase inhibitor and androgen receptor (AR) antagonist with approximately 10-fold selectivity for inhibition of 17,20-lyase over 17α-hydroxylase. Docetaxel is a taxane chemotherapy agent. Laboratory data has demonstrated that this combination can suppress metastatic TNBC growth and increase survival by blocking chemotherapy-induced cell plasticity.

Targets

MicrotubuleER (Estrogen receptor)CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)AR (Adrenergic receptors)

Beyond the preview

Go deeper on seviteronel + docetaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on seviteronel + docetaxel.

Explore the full profile